Report scope. This 2026 Drug Asset Due Diligence Report evaluates Orismilast as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.
Executive recommendation: HOLD / OPTION
Orismilast is a Small molecule drug associated with PDE4B x PDE4D and a global highest development stage of Phase 2. The lead disclosed indication is Autoimmune Diseases. The current evidence supports a HOLD / OPTION posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.
Decision memo
- Asset: Orismilast
- Target: PDE4B x PDE4D
- Lead indication: Autoimmune Diseases
- Highest phase: Phase 2
- Matched trials: 0
- Matched result records: 6
- Matched asset deals: 2
Use PatSnap Life Sciences MCP servers to validate the Orismilast diligence evidence.
1. Asset identity and development status
The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For Orismilast, the MCP profile identifies PDE4B x PDE4D as the primary target context and Autoimmune Diseases as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.
Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.
Use PatSnap Life Sciences MCP servers to validate the Orismilast diligence evidence.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| No asset-specific registered study was returned by the MCP query. Confirm sponsor records and registry synonyms before a licensing decision. | ||||
The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.
Use PatSnap Life Sciences MCP servers to validate the Orismilast diligence evidence.
3. Clinical readouts: what is known
ORISMILAST FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS: A PROOF OF CONCEPT TRIAL
Study: UCORIS (UEGW2025). Phase: Phase 2. Enrollment: 10. Published: 2025-10-05.
clinical remission(12-week) = 1.0 Pts
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults With Moderate to Severe Atopic Dermatitis
Study: NCT05469464 (CTgov). Phase: Phase 2. Enrollment: 235. Published: 2025-03-07.
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16(LS Mean) = -55.1 % | Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16(LS Mean) = -52.2 %
UNION therapeutics announces presentation of preliminary data from Phase 2a investigator-initiated study with orismilast in ulcerative colitis at the 20th ECCO Congress
Study: UCORIS (PRNewswire). Phase: Phase 2. Enrollment: 10. Published: 2025-02-21.
CR = 3 Pts
P0942 Orismilast for the treatment of moderate to severe Ulcerative Colitis: Analysis of preliminary data from UCORIS, a phase 2a, open-label, single-arm exploratory clinical trial
Study: UCORIS (ECCO2025). Phase: Phase 2. Enrollment: 9. Published: 2025-02-19.
clinical remission(12-week) = 1.0 Pts
UNION therapeutics announce results from the ADESOS Phase 2b study in atopic dermatitis confirming the potential of orismilast as a first-in-class safe and efficacious oral treatment
Study: NCT05469464 (PRNewswire). Phase: Phase 2. Enrollment: 233. Published: 2024-09-25.
EASI(16-week) = -55.1 % | EASI(16-week) = -52.2 %
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults With Moderate-to-Severe Plaque-Type Psoriasis
Study: NCT05190419 (IASOS, CTgov). Phase: Phase 2. Enrollment: 202. Published: 2024-04-16.
Percent Change From Baseline in Psoriasis Activity and Severity Index (PASI) Score at Week 16(LS Mean) = -17.30 % | Percent Change From Baseline in Psoriasis Activity and Severity Index (PASI) Score at Week 16(LS Mean) = -52.60 %
For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.
Use PatSnap Life Sciences MCP servers to validate the Orismilast diligence evidence.
4. Market and competitive position
The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark Orismilast against approved therapies and clinical competitors in Autoimmune Diseases, including likely standards of care at the expected launch date.
Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.
Use PatSnap Life Sciences MCP servers to validate the Orismilast diligence evidence.
5. Transaction precedent and economics
| Date | Transaction | Status | Type | Disclosed value |
|---|---|---|---|---|
| 2021-09-27 | Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions | Active | License | 267 |
| 2020-07-21 | UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2 | Active | License | Not disclosed |
Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.
6. IP and freedom-to-operate screen
Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.
The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.
Use PatSnap Life Sciences MCP servers to validate the Orismilast diligence evidence.
7. Principal risks and diligence gates
- Identity risk: resolve all aliases, formulations, combinations, and owners.
- Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
- Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
- IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
- CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
- Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
- Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.
8. Final go/no-go memorandum
HOLD / OPTION
Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.
Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-15. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.
